PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dorzolamide and timolol - Glaucoma
PAD Profile : Dorzolamide and timolol - Glaucoma
Brand Names Include :
Cosopt, Eylamdo, Vizidor Duo
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 December 2021
Committee Recommendations
Date
Committee Name
Narrative
22 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Primary care prescribers do not have the necessary equipment or skills to perform ocular pressure readings to make a diagnosis. The APC recomments that this product, when used for treatment of glaucoma, should be considered as BLUE.
Note; the branded product (Cosopt) was considered as BLACK at the PCN in May 2017.
Associated BNF Codes
11. Eye
11.06.00. Treatment of glaucoma